GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November 2025, as drugmakers ramped up efforts to meet surging demand and expand their metabolic portfolios.
According to Bain & Co.’s Global M&A Report 2026, the spike in activity reflects a shift in strategy: Acquirers are no longer focused solely on individual products, but are instead building full-platform control. That includes securing proprietary delivery technologies, expanding manufacturing capacity and investing in next-generation mechanisms.
This evolution is also reshaping the structure of deals. Bain said transactions are becoming larger and more technically complex, with several including manufacturing tie-ups aimed at alleviating production bottlenecks. At the same time, companies are broadening their pipelines through investments in oral formulations and dual- and triple-agonist therapies.
Beyond infrastructure and R&D, the report points to a growing focus on commercial strategy. As GLP-1s move further into chronic disease management and consumer wellness, Bain said the greatest value will accrue to companies that can integrate innovation, scale supply and connect directly with patients.
GLP-1 makers now account for a significant share of pharma deal value, and Bain expects they will continue to lead sector activity into 2026.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
